A
Anita M. van den Hoek
Researcher at Netherlands Organisation for Applied Scientific Research
Publications - 48
Citations - 2635
Anita M. van den Hoek is an academic researcher from Netherlands Organisation for Applied Scientific Research. The author has contributed to research in topics: Insulin resistance & Steatohepatitis. The author has an hindex of 21, co-authored 40 publications receiving 2056 citations. Previous affiliations of Anita M. van den Hoek include University of Groningen & Leiden University Medical Center.
Papers
More filters
Journal ArticleDOI
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Frederick E. Dewey,Viktoria Gusarova,Richard L Dunbar,Colm O'Dushlaine,Claudia Schurmann,Omri Gottesman,Shane McCarthy,Cristopher V. Van Hout,Shannon Bruse,Hayes Dansky,Joseph B. Leader,Michael F. Murray,Marylyn D. Ritchie,H. Lester Kirchner,Lukas Habegger,Alex Lopez,John Penn,An Zhao,Weiping Shao,Neil Stahl,Andrew J. Murphy,Sara Hamon,Aurelie Bouzelmat,Rick Zhang,Brad Shumel,Robert Pordy,Daniel A. Gipe,Gary Herman,Wayne H-H Sheu,I-Te Lee,I-Te Lee,Kae-Woei Liang,Kae-Woei Liang,Xiuqing Guo,Jerome I. Rotter,Yii-Der Ida Chen,William E. Kraus,Svati H. Shah,Scott M. Damrauer,Aeron Small,Daniel J. Rader,Anders Berg Wulff,Børge G. Nordestgaard,Anne Tybjærg-Hansen,Anita M. van den Hoek,Hans M.G. Princen,David H. Ledbetter,David J. Carey,John D. Overton,Jeffrey G. Reid,William J. Sasiela,Poulabi Banerjee,Alan R. Shuldiner,Ingrid B. Borecki,Tanya M. Teslovich,George D. Yancopoulos,Scott Mellis,Jesper Gromada,Aris Baras +58 more
TL;DR: Genetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease.
Journal ArticleDOI
Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology
Wen Liang,Aswin L. Menke,Ann Driessen,Ger H. Koek,Jan H.N. Lindeman,Reinout Stoop,Louis M. Havekes,Robert Kleemann,Anita M. van den Hoek +8 more
TL;DR: A modified generic scoring system with high reproducibility that is applicable for different rodent models and for all stages of NAFLD etiology is established.
Journal ArticleDOI
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kühnast,Susan Kühnast,José W.A. van der Hoorn,José W.A. van der Hoorn,Elsbet J. Pieterman,Anita M. van den Hoek,William J. Sasiela,Viktoria Gusarova,Anusch Peyman,Hans-Ludwig Schäfer,Uwe Schwahn,J. Wouter Jukema,Hans M.G. Princen +12 more
TL;DR: Alirocumab dose-dependently decreases plasma lipids and, as a result, atherosclerosis development, and it enhances the beneficial effects of atorvastatin in APOE*3Leiden.CETP mice.
Journal ArticleDOI
Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance
Robert Kleemann,Marjan van Erk,Lars Verschuren,Anita M. van den Hoek,Maud Koek,Peter Y. Wielinga,Annie Jie,Linette Pellis,Ivana Bobeldijk-Pastorova,Thomas Kelder,Karin Toet,Suzan Wopereis,Nicole H.P. Cnubben,Chris T. Evelo,Ben van Ommen,Teake Kooistra +15 more
TL;DR: HFD-induced IR is a time- and tissue-dependent process that starts in liver and proceeds in WAT and is paralleled by tissue-specific gene expression changes, metabolic adjustments, changes in lipid composition, and inflammatory responses in Liver and WAT involving p65-NFkB and SOCS3.
Journal ArticleDOI
Metformin lowers plasma triglycerides by promoting vldl-triglyceride clearance by brown adipose tissue in mice
Janine J. Geerling,Mariëtte R. Boon,Gerard C.M. van der Zon,Sjoerd A.A. van den Berg,Anita M. van den Hoek,Marc Lombès,Hans M.G. Princen,Louis M. Havekes,Patrick C.N. Rensen,Bruno Guigas +9 more
TL;DR: In this paper, the authors investigated the underlying mechanisms in APOE*3-Leiden mice and found that metformin markedly lowered plasma total cholesterol and TG levels, an effect mostly due to a decrease in VLDL-TG whereas high-density lipoprotein was slightly increased.